Masimo (MASI) Immaterializes SEDline (HSP) Acquisition (MASI, HSP)

Yesterday, Masimo Corporation MASI announced that the acquisition made by SEDline of brain monitoring system manufacturer Hospira, Inc. HSP is immaterial, as it is dilutive to 2010 EPS. However, they added, it makes strategic sense. Analysts at Morgan Keegan feel that Masimo will be able to use its brand-name and global sales-force in expanding the presence of SEDLine, as both their products are used by anaesthesiologists. Masimo has provided funds to SEDline in the form of $3 million in loans and $500,000 in cash to acquire IP. The analyst gave Outperform ratings to Masimo with Market Risk Suitability. See Some of the Top Moving Indexes Here.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!